ERBB2 and ductal breast carcinoma in situ: HER2-positive subtype in DCIS-Mi accounted for less of the overall population (32.1%) when compared with HER2-positive tumors (42.9%), mainly because HER2-positive tumors consisted of both luminal-B and HER2-positive subtypes.